| Drug Name |
Aliskiren hemifumarate |
| Drug ID |
BADD_D00074 |
| Description |
Aliskiren is the first drug in the renin inhibitor drug class and is used for the treatment of hypertension.[A203624] It was developed by Speedel and Novartis and initially approved by the FDA in early 2007.[L14018] Aliskiren has been proven to efficacious in reducing blood pressure when used alone or in conjunction with other antihypertensive agents.[A203624] |
| Indications and Usage |
Aliskiren is used for the treatment of hypertension in children above 6 years and adults.[L13994] This drug may also be used in conjunction with antihypertensives such as calcium channel blockers and thiazides in products form to provide additional blood pressure control.[L14168,L14171] |
| Marketing Status |
approved; investigational |
| ATC Code |
C09XA02 |
| DrugBank ID |
DB09026
|
| KEGG ID |
D06412
|
| MeSH ID |
C446481
|
| PubChem ID |
6918427
|
| TTD Drug ID |
D03SVX
|
| NDC Product Code |
12666-0016; 66993-141; 14501-0062; 65372-1178; 71973-152; 71973-301; 66993-142; 70839-150; 70839-300 |
| UNII |
C8A0P8G029
|
| Synonyms |
aliskiren | rasilez | Tekturna | CGP 060536B | CGP060536B | CGP-060536B | 2(S),4(S),5(S),7(S)-N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate | SPP100 |
